newsfilter
← Latest News
Business Wire·

Forte Biosciences Announces Positive Data in FB102 Celiac Disease Phase 1B Study

Phase 2 Celiac Disease Trial Initiating with Topline Readout Expected in 2026 Forte will be Hosting a Conference Call to Discuss the Results at 8:30 am ET Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ:FBRX),